Nonmedicated control substances Show Limited Efficacy in Chronic Sinusitis: Study

Written By :  MD Bureau
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-03-10 04:30 GMT   |   Update On 2021-03-10 04:26 GMT

Chronic rhinosinusitis (CRS) is a significant health problem and affects 5% to 12% of the general population. A study published in the JAMA Otolaryngology-Head & Neck Surgery on November 12, 2020, suggests that nonmedicated control substances are associated with limited improvements in the 22-item Sinonasal Outcome Test and nasal obstruction scores.CRS is a clinically challenging disease;...

Login or Register to read the full article

Chronic rhinosinusitis (CRS) is a significant health problem and affects 5% to 12% of the general population. A study published in the JAMA Otolaryngology-Head & Neck Surgery on November 12, 2020, suggests that nonmedicated control substances are associated with limited improvements in the 22-item Sinonasal Outcome Test and nasal obstruction scores.

CRS is a clinically challenging disease; as in asthmatic patients, symptoms lack good correlation with objective measurements because of the lack of a gold standard. It is usually treated with nasal corticosteroids, over-the-counter medications or non-medicated substances like saline nasal irrigation/nasal sprays. However, the effect of nonmedicated control substances in chronic rhinosinusitis remains unclear. Therefore, Dr Lisa Caulley and team conducted a study to assess the association of nonmedicated control substances in randomized clinical trials with disease outcomes in patients diagnosed with chronic rhinosinusitis.

It was a single-arm systematic review and meta-analysis. Researchers evaluated the databases of the Cochrane Library of Systematic Reviews, Ovid MEDLINE, Embase, PubMed, and ClinicalTrials.gov for randomized clinical trials with a preintervention and postintervention design for chronic rhinosinusitis that were published between 1946 and January 23, 2019. Paired reviewers independently extracted data. The major outcomes assessed were the association of nonmedicated control substances with 22-item Sinonasal Outcome Test (SNOT-22) scores or nasal symptom scores when SNOT-22 was not available. Researchers screened a total of 2305 abstracts and included 38 articles in the meta-analysis.

Key findings of the study were:

• Upon analysis, they found that the topical nonmedicated control substances were associated with a significant reduction in SNOT-22 scores (mean difference [MD], −8.81).

• They conducted a subgroup analysis of topical therapies, limited to saline irrigation and nasal spray diluents and found that topical diluents were associated with a greater reduction in SNOT-22 scores (MD, −11.45) compared with saline irrigation (MD, −13.60).

• They also found that nonmedicated control substances were associated with a significant reduction in nasal obstruction scores (standardized MD [SMD], −0.42).

• However, they found no significant changes in rhinorrhea scores (SMD, −0.34), postnasal drip scores (SMD, −0.96), facial pain scores (SMD, −0.57), or loss of smell scores (SMD, −0.18).

The authors concluded, " This systematic review and meta-analysis of the use of nonmedicated control substances in randomized clinical trials of chronic rhinosinusitis outcomes suggest that the use of nonmedicated control substances is associated with limited improvements in SNOT-22 and nasal obstruction scores."

They further added, "These findings highlight potential areas of future research directions and the importance of randomized clinical trials to accurately estimate the treatment effect."

For further information:

https://jamanetwork.com/journals/jamaotolaryngology/article-abstract/2772878


Tags:    
Article Source :  JAMA Otolaryngology-Head & Neck Surgery

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News